[Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn [Table_Industry] [Table_BaseData] 1) 区间回顾。2 月 9 日-2 月 27 日，医药生物板块跌 0.32%，跑输 Wind 全 A（3.89%）和沪深 300（1.44%）。 从细分板块来看，医疗耗材（3.64%）、其他生物制品 （2.78%）和原料药（0.68%）领涨，线下药店（-2.12%）、 化学制剂（-1.53%）和医药流通（-1.37%）领跌。从个 股来看，万泽股份（44.06%）、科源制药（34.82%）和 多瑞医药（20.77%）涨幅居前，国发股份（-10.19%）、 泽璟制药-U（-10.18%）和花园生物（-9.4%）跌幅居 前。 2) 测序仪龙头押注技术跃迁。2 月 23 日，华大智造公告 与瑞士 Swiss Rockets 达成战略交易，以 5000 万美元 对价出售美国子公司 CGI 股权并锁 ...

Core Viewpoint - Zhongheng Group (600252) anticipates a negative net profit for the fiscal year 2025, indicating a significant operational loss [1] Group 1: Financial Performance - The company reported a drastic decline in net profit for 2024, with a year-on-year decrease of 547.14% to -377 million yuan, marking the second annual loss since its listing [1][2] - In the first three quarters of 2025, the company achieved total revenue of 1.948 billion yuan, a year-on-year increase of 1.10%, and a net profit of 24.64 million yuan, up 119.61% [2] - Despite the profit growth in early 2025, the company expects a negative net profit for the entire year, indicating substantial losses in the fourth quarter [2] Group 2: Key Financial Metrics - The company's gross margin plummeted from 61.45% in 2023 to 43.21% in 2024, and further down to 31.92% in the first three quarters of 2025 [2] - The net profit margin deteriorated from 0.98% in 2023 to -24.27% in 2024, remaining at -0.48% in the first three quarters of 2025 [2] Group 3: Debt and Financial Position - As of the end of the third quarter of 2025, short-term borrowings increased by 21.4% compared to the end of the previous year, accounting for a 2.43% rise in total assets [3] - Long-term borrowings rose by 47.52%, contributing to a 1.94% increase in total assets [3]